
MyMD is a clinical-stage pharma company developing therapeutic platforms for autoimmune diseases and aging, and a novel CBD derivative.
On September 22, 2025, the company changed its name from TNF Pharmaceuticals, Inc. to Q/C Technologies, Inc., and it seeks to develop proprietary photonic processing units positioned against electronic GPUs. TNF holds exclusive rights to the use of its computing technology in cryptocurrency and blockchain applications. The previous names listed are MyMD Pharmaceuticals, Inc. and Akers Biosciences, Inc.
The company seeks to develop proprietary photonic processing units that perform matrix multiplication via optical interference, overcoming challenges posed by electronic GPUs. The technology is designed to tackle blockchain development challenges including high energy consumption, scalability limits, and rising operational costs.

Integrated BioPharma
ibiopharma.com

Alternate Health

Quolet Industries
quolet.com

Pure Green Pharmaceuticals
pgpharma.co
THC Farmaceuticals
toke.city

Qnovia
qnovia.com

CNBX Pharmaceuticals
cnbxpharma.com

Kyntra Bio
fibrogen.com

Tenax Therapeutics
tenaxthera.com

D&D Pharmatech

Day Three Labs
daythreelabs.com

Emerald Health Pharmaceuticals
emeraldpharma.life

QHSLab
usaqcorp.com

Skye Bioscience
skyebioscience.com
Applied Biosciences

Quark Pharmaceuticals

Navigator Medicines

Diverse Biotech
Apollo Therapeutics

Aquavit Pharmaceuticals
aquavitpharma.com
Companies similar to Q/C Technologies include Integrated BioPharma, Alternate Health, Quolet Industries and Pure Green Pharmaceuticals.
Q/C Technologies was founded in 2014.
Q/C Technologies' headquarters is located in New York, NY, US.
Q/C Technologies' most recent funding round was for $15M (USD) in February 2023.
As of Feb 21, 2023, Q/C Technologies has disclosed funding of $15M (USD).
Q/C Technologies has 9 employees as of Feb 6, 2024.